Our Therapeutics Pipeline

Current research works

Our current research works

Novel Cancer Therapeutic Drugs

Since early 2022, CancerAppy has been dedicated to discovering and developing novel therapeutic targets for cancer.

This has been made possible through the advancement of our AI-driven platform, developed in collaboration with our scientific team and advisors

MECHANISM / INDICATION

Discovery             |                        Pre-Clinical                     |                    IND-Enablig            |        Phase I

ADCGEN-04 - (ADC)* (Licensed)

ADCGEN-04 is a first-in-class Antibody-Drug Conjugate (ADC) developed for the treatment of several solid tumors, targeting a novel and unexplored antigen with no direct competition.

It combines a high-affinity monoclonal antibody (mAb) with a potent cytotoxic payload, linked through a stable and tumor-specific cleavable linker.

*A pre-licensing agreement has been signed with a U.S. company.

  • 40%40%
CA09-SM Next-generation TEAD inhibitor

CA09 is a TEAD inhibitor targeting a well-established oncogenic pathway involved in cancer development. TEAD is overexpressed in multiple tumors and plays a key role in downstream signaling by enabling coactivators to transmit cellular signals.

CA09 inhibits the YAP/TAZ pathway through a dual mechanism, combining orthosteric and allosteric inhibition via different small molecules.

The compound has shown no major red flags in development, supporting its clinical progression. While several companies are working on TEAD inhibitors, CA09 differentiates itself by focusing on biomarker-driven patient selection, identifying specific mutations for precision oncology applications.

Its target population includes various epithelial tumors, with a primary focus on Head & Neck Cancer and Breast Cancer.

With a global market potential across multiple oncology indications, CA09 represents a promising next-generation TEAD inhibitor with a unique patient selection strategy. 

  • 25%25%

The rapid growth of the internal pipeline demonstrates the great drug discovery capabilities driven by the use of our AI platform.

Likewise, our partners and collaborators take advantage of our technology and high scientific knowledge to increase and accelerate their initiatives for the discovery and development of new drugs against cancer.

Target Identification

We combine our expertise in biology and AI to identify new therapeutic targets.

Lead Identification

We combine our expertise in chemistry and AI to identify new chemical compounds with the potential to be novel inhibitors of therapeutic targets.

Mechanism of action

We can find the possible mechanism of action of a compound.

Request an interview

The programs below are progressing into the early preclinical stage.

However they are programs that are available under CDA.

Contact us for partnership opportunities.